McMurray JJV, Jackson AM, Lam CSP, et al. - Researchers performed a prespecified subgroup analysis analyzing outcomes according to gender in the PARAGON-HF trial which compared sacubitril-valsartan and valsartan in patients with heart failure with preserved ejection fraction. Randomization of 2,479 women (51.7%) and 2,317 men (48.3%) was done. Relative to men, women were older, had more obesity, less coronary disease, and lower estimated glomerular filtration rate and NT-proBNP levels. Women seemed to have a higher reduction in the risk of heart failure hospitalization than men in correlation to receiving sacubitril-valsartan vs valsartan. While several potential explanations are there for the possible gender-related modification of the effect of treatment, the present study provides no definite mechanistic basis for this finding.